Pediatric Dermatology

Latest News


CME Content


SkinMedica extends TNS line

SkinMedica, Carlsbad, Calif. is introducing three new products at the 63rd annual meeting.

As a dermatologist for 27 years, Norman Levine, M.D., professor of dermatology, University of Arizona College of Medicine, Tucson, and editorial advisor to Dermatology Times, has gathered new insights from clinical experience, reference books, professional meetings and reviews of treatment modalities.

Kissimmee, Fla. — The sale of cosmeceuticals in dermatology offices may have become commonplace, but some contention still surrounds physician involvement in selling skincare products.

Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.

The efficacy and remarkable safety profile of two drugs, tacrolimus (Protopic?, Fujisawa Healthcare) and pimecrolimus (Elidel?, Novartis), have revolutionized the treatment of atopic dermatitis (AD) and appear to have promise for a variety of other inflammatory skin conditions that require long-term therapy, according to Alan Fleischer, M.D., professor and chair of dermatology at Wake Forest University School of Medicine.

The efficacy and remarkable safety profile of two drugs, tacrolimus (Protopic?, Fujisawa Healthcare) and pimecrolimus (Elidel?, Novartis), have revolutionized the treatment of atopic dermatitis (AD) and appear to have promise for a variety of other inflammatory skin conditions that require long-term therapy, according to Alan Fleischer, M.D., professor and chair of dermatology at Wake Forest University School of Medicine.

We are all teachers in dermatology whether we are solo private practitioners, group practitioners, academic practitioners, research practitioners or industry practitioners.

New York — Interest in tumescent liposuction has expanded to a variety of new indications, including postmenopausal "lumpy" back fat deposits and as an alternative to more invasive procedures such as abdominoplasty and surgical mammoplasty, according to Naomi Lawrence, M.D.

Newport Beach, Calif. — Based on two cases, Japanese dermatologist Hideo Nakayama, M.D. has identified the Blue Star flower (Oxypetalum caeruleum) as a new sensitizer for contact dermatitis.

Buenos Aires — "Controle sus lunares por una piel sana" (control your moles for a healthy skin) is a message that people throughout Argentina heard repeatedly last November, thanks to the efforts of Rebeca Rubinson, M.D., and her colleagues at the Sociedad Argentina de Dermatologia (SAD) here. Dr. Rubinson is a pediatric dermatologist affiliated with Hospital Abel Zubizarreta in Buenos Aires and the coordinator of the 2004 campaign on recognition and prevention of skin cancer.

Jazz up the night

Unwind after a long day at the convention center with nightlife that only New Orleans can provide. Stroll down Bourbon St. or check out one of these hot spots.

Miami Beach, Fla. — "Make sure you really see what you're looking at." A point that might well be called the "Klein Oath" for all cosmetic procedures, was what Botox pioneer Arnold W. Klein, M.D. repeatedly emphasized as he addressed the topic "Botulinum Toxin Type A 2004: My Perspective" at the H & H Dermatology Seminar here.

Kissimmee, Fla. — In dermatology practices today, two basic types of procedures exist: "desire-based" cosmetic procedures and "disease-based" procedures, such as the removal of a skin cancer. Traditionally in medicine, physicians have employed a set of relatively objective criteria to define an acceptable outcome in the second type of procedure. It is the first category, elective and cosmetic procedures, where the physician must satisfy another, more subjective, set of criteria — one that is frequently the cause of disappointment, remorse, dissatisfaction, anger and, all too often, malpractice litigation.

San Francisco — Along with helping patients, the advent of biologic drugs has restored some much-needed luster to the practice of medical dermatology.

Las Vegas — With the increased efficacy of topical immune modulators in the treatment of atopic dermatitis, Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology and clinical professor of pediatrics and dermatology at the Children'sHospital in San Diego and University of California, San Diego, has established a step approach to the treatment of atopic dermatitis.

Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.